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Abstract: Pathogenic antibiotic resistant bacteria pose one of the most important health challenges
of the 21st century. The overuse and abuse of antibiotics coupled with the natural evolutionary
processes of bacteria has led to this crisis. Only incremental advances in antibiotic development
have occurred over the last 30 years. Novel classes of molecules, such as engineered antibodies,
antibiotic enhancers, siderophore conjugates, engineered phages, photo-switchable antibiotics, and
genome editing facilitated by the CRISPR/Cas system, are providing new avenues to facilitate
the development of antimicrobial therapies. The informatics revolution is transforming research
and development efforts to discover novel antibiotics. The explosion of nanotechnology and
micro-engineering is driving the invention of antimicrobial materials, enabling the cultivation of
“uncultivable” microbes and creating specific and rapid diagnostic technologies. Finally, a revival
in the ecological aspects of microbial disease management, the growth of prebiotics, and integrated
management based on the “One Health” model, provide additional avenues to manage this health
crisis. These, and future scientific and technological developments, must be coupled and aligned
with sound policy and public awareness to address the risks posed by rising antibiotic resistance.
Keywords: antibiotics; resistance; antibiotic targets; antimicrobial materials; microbiome
1. Introduction
Bacteria that are resistant to clinically relevant antibiotics are a major threat to public health
worldwide. Factors leading to this crisis, such as the lack of research and development of novel
antibiotics, have been examined elsewhere [1–3]. The recent global status of antibiotics has been
documented in a policy document issued by the Center for Disease Dynamics, Economics, and Policy
(CDDEP) [4]. The development of antibiotics was rapid between 1940–1962, when 20 clinically relevant
classes were discovered and developed; only two major novel classes have been commercialized
since 1962. Large pharmaceutical companies in recent decades have committed scant resources to
antibiotics [5], as drugs treating lifestyle diseases yield more sustainable profits. Meanwhile, academic
scientists, smaller companies, non-profits, and academic-industry partnerships have brought about
significant developments in the fields of antibiotics and antimicrobial strategies.
For example, the tuberculosis-focused TB Alliance initiated Phase I trials for TBA-7371,
which belongs to a new class of compounds called DprE1 inhibitors that block the enzyme
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decaprenylphosphoryl-β-d-ribose 2′-epimerase (DprE1) in the cell wall biosynthesis of Mycobacterium
tuberculosis. Only two TB drugs have been approved for clinical use in recent years, namely,
Johnson and Johnson’s bedaquiline and Otsuka Pharmaceutical’s delamanid, both for treating
multi-drug-resistant tuberculosis. More needs to be done on this front as resistance to known drugs is
rising. A new business model for the development of antibiotics that is not dependent on high returns
from the large volume product sales has been advocated [6]. This article offers snapshots from the
gamut of recent antimicrobial science and technology, including antimicrobial discovery strategies,
novel antibiotic types, newer antimicrobial materials, emerging commercial technology platforms,
and microbial ecology management, including microbiome interventions. This article is restricted to
developments mainly arising in the last decade, and earlier approaches that are being revived due to
increasing antibiotic resistance.
2. Novel Targets, Discovery Approaches, and Sources
2.1. Novel Antibiotic Targets
Traditionally, antibiotics have targeted mainly bacterial DNA replication, protein synthesis, or
peptidoglycan synthesis. Widespread resistance has caused researchers to search for newer targets for
combating bacterial infections; an overview is shown in Table 1. The nine nutritionally essential amino
acids, namely, leucine, isoleucine, valine, threonine, methionine, tryptophan, phenylalanine, histidine,
and lysine are synthesized by bacteria, but not by humans. In addition to protein synthesis, lysine is also
involved in bacterial peptidoglycan biosynthesis. The L,L-diaminopimelate aminotransferase (DapL)
pathway for lysine biosynthesis was recently identified as a novel variant occurring in pathogenic
genera such as Chlamydia, Leptospira, and Treponema [7]. DapL inhibitors are potential narrow-spectrum
antibiotics given the narrow distribution of the enzyme among the bacterial kingdom [8]. Aromatic
amino acid biosynthesis also affords multiple antibiotic targets. Four shikimate pathway enzymes are
essential for the gastric pathogen, Helicobacter pylori; shikimate kinase and type II dehydroquinase are
important for both Mycobacterium tuberculosis and Helicobacter pylori, and inhibitors of these enzymes
are under development [9]. The Tuberculosis Structural Genomics Consortium (TBSGC) has facilitated
the solving of X-ray diffraction structures of many Mycobacterium tuberculosis proteins, including
several from the tryptophan biosynthetic pathway, namely, TrpB, TrpC, and TrpE, and inhibitory
molecules were discovered [10–12]. The shikimate pathway is also essential for parasitic protozoa,
such as Toxoplasma gondii and Plasmodium falciparum, and identifying the relevant genes could spur the
production of selective anti-parasitic molecules [13,14].
The generation of spontaneous suppressor mutants and a comparison of the genomes of
telomycin-sensitive versus resistant cells of Staphylococcus aureus and Bacillus subtilis revealed mutations
in genes encoding for the phospholipid cardiolipin, suggesting cardiolipin biosynthesis as a new
antibiotic target [15]. Teixobactin is a new antibiotic that inhibits cell-wall biosynthesis by binding
the lipid-pyrophosphate-sugar motif of Lipid II (precursor of peptidoglycan), and of Lipid III of wall
teichoic acid in Gram-positive bacteria. Since the structure of Lipid II is not expected to change much via
mutations, teixobactin is predicted to be free from bacterial resistance [16]. The compound POL70780 is
a Pseudomonas aeruginosa-specific inhibitor of LptD, a protein involved in lipopolysaccharide insertion
to the outer membrane [17]. Since LptD is well-conserved across bacterial species and the rate of
mutations is low, similar compounds could be developed against other pathogens. A recent study
identified a tripeptide “staphylopine” in Staphylococcus aureus that binds nickel, cobalt, zinc, copper,
and iron [18]. The biosynthetic pathway for this peptide was elucidated and several genes in the
corresponding gene cluster were conserved in other pathogens, such as Yersinsia pestis and Pseudomonas
aeruginosa, suggesting that molecules interfering with staphylopine biosynthesis could potentially act
as broad-spectrum antibiotics.
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Table 1. Emerging targets for antibiotic research and development, current discovery approaches, and
potential sources for novel antibiotics.
Novel Targets Identified
with References Discovery Approaches Sources
Essential amino acid
biosynthesis [7–14] Informatics-based mining Medicinal plants
Cell wall lipid
biosynthesis [15,16]
Cryptic Biosynthetic Gene
Clusters (BGC) activation
• Antibiotic stimulation
• Quorum sensing signals
• Specific pathway inhibitors
Marine invertebrates
Lipid insertion
enzymes [17] Insect and vertebrate symbionts
Metal chelator
biosynthesis [18] Microbial co-cultures
Quorum sensing
metabolism [19–31]
BGC engineering
• Special plasmids
• Engineered pathways
• Replacing native promoters
Endophytic fungi and bacteria
Clp proteases [32,33] Uncultured microbes
Cyclic-di- Guanosine
monophosphate (GMP)
levels [34]
Skin, blood, venoms
Quorum sensing (QS) is a process whereby bacterial signalling molecules are produced and
detected in order to coordinate cell-density based behavioral changes [19]. An estimated 80% of all
microbial infections are associated with biofilms. Disrupting QS can prevent the formation of biofilms,
increasing the importance of quorum sensing inhibitors (QSI). Since QS is not directly involved in cell
wall biosynthesis or DNA replication, as anti-virulence factors QSI afford an alternative mechanism
compared to traditional antibiotics. The major QS systems are the acyl-homoserine lactone (AHL) of
Gram-negative bacteria [19], the auto-inducing peptide (AIP) system of Gram-positive bacteria [20],
and the autoinducer-2 (AI-2), which occurs in both groups [21,22]. Inhibitors of the Lux protein family
interfere with AHL-based QS and prevent biofilm formation, which enables the antibiotic azithromycin
to clear chronic Pseudomonas infections in animal models [23]. Substrate analogues and inhibitors of
all three QS systems have been reviewed elsewhere [24]. Notably, two proteins in the AI-2 pathway,
LuxS and 5’methylthioadenosine nucleosidase (MTAN), are found in bacteria but not in mammals,
leaving further scope for using these as targets for new antibiotics [25–28]. Enzymes, such as acylases,
lactonases, and oxidoreductases can degrade or modify AHL signals, a phenomenon termed quorum
quenching (QQ) [29]. QQ enzymes are found in bacteria, plants, and mammals. The non-AHL QS
systems are not susceptible to QQ, but they have been targeted by antibodies against AIP produced by
Staphylococcus aureus [30] and AI-2 produced by Salmonella enterica serovar Typhimurium [31].
Lassomycin is a new peptide active against Mycobacterium tuberculosis produced by an
Actinomycete, Lentsea sp [32]. It inhibits an essential protease ClpP1P2C1 and increases its ATP-ase
activity, thereby killing both growing and dormant cells. Traditional antibiotics usually only kill actively
growing cells and persistence of dormant cells remains a recurring problem. The acetyldepsipeptide
ADEP4 activates the ClpP protease that degrades misfolded proteins with the help of ATP-dependent
chaperones [33]. ADEP4 and its analogues, however keep the channel of ClpP open, obviating the
need for ATP hydrolysis. Thus, ADEP4 became the first antibiotic to effectively kill persister cells in
biofilms. Although resistance to ADEP4 is common, combining it with other antibiotics eradicated
biofilms in vitro and in mouse models. Well-known food items, like spices, also contain antibiotic
compounds, whose mechanisms of action are being investigated. Ginger contains raffinose, which
inhibits biofilms of Pseudomonas aeruginosa by decreasing the intracellular levels of cyclic-di-GMP, thus
inducing a switch from non-motile (biofilm) to motile (planktonic) cells [34]. Growth of the pathogen
is not affected, suggesting that limiting cyclic-di-GMP could be a way to clear biofilm formation.
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2.2. Novel Discovery Approaches
2.2.1. Informatics-Based Discovery Approaches
Newer genomics approaches are beginning to overtake old “Grind and Find” methods of first
cultivating microbes and then extracting compounds in the hunt for new antibiotics [35]. A platform
that allows the mining of antibiotic biosynthetic gene clusters (BGC) based on similarity to known
examples from plants, fungi, and bacteria is the antibiotics and Secondary Metabolite Analysis Shell
(antiSMASH) tool [36,37]. Another recent portal mines the genes encoding for the biosynthesis of a
particular natural product and uses that knowledge to probe whether or not other strains can make
specific important intermediates of the natural product [38]. Alternatively, mining with narrow focus
on genes involved in the final few steps of biosynthetic pathways enables the identification and
optimization of variants, potentially producing an entire class of analogues using the results of just
one study.
Genomic analysis can also reveal the presence of repressors or activators of biosynthesis genes,
paving the way for engineering strains with overproduction capabilities [39]. However, only a
fraction of bacterial diversity is routinely cultivated, and therefore, only a small percentage of the
chemistries have been sampled. Many existing bioinformatics platforms have a bias towards known
molecules, adding to the redundancy of frequent rediscovery. Among Actinomycetes, Streptomyces is
over-represented due to sampling bias arising from different sources [40]. Shotgun sequencing of soil
metagenomes remains an unsatisfactory tool for antibiotic discovery, since it remains challenging to
sequence deep enough to obtain usable information about BGC [41]. Recently, a barcoding approach
using degenerate polymerase chain reaction (PCR) primers to parse mixtures of BGC present in
environmental samples via the environmental Surveyor of Natural Product Diversity (eSNaPD) server
was formulated [42]. A survey of calcium-dependent antibiotics in diverse soil metagenomes based on
eSNAPD analysis showed that more than 70% of BGC were unique to individual metagenomes, and
led to the discovery of the malacidins, a novel family of antibiotics, which did not develop resistance
under laboratory conditions [43].
A comprehensive bio- and chemo-informatics study of all currently known antibiotics was
published, wherein 54 distinct molecular targets were identified [15]. The authors created a public
web application called “Antibioticome” that defines the chemical origins and families of known
natural antibacterials and their targets. An algorithm described as “retrobiosynthetic”, i.e., capable
of identifying the chemical building blocks from which each antibiotic originates, was used. Since
metadata pertaining to known or suspected mechanisms of action were also incorporated, the method
was able to identify candidates with unknown modes of action. Antibiotic resistance often originates
from the biosynthetic gene clusters in antibiotic-producers. Therefore, another web application was
created to correlate self-resistance with known antibacterial mechanisms allowed for the scanning
of BGC for homology to resistance genes and predict antibiotic targets. The application was able to
correctly predict that the non-ribosomal peptide telomycin had a potentially unique mechanism of
action [15]. The ease and economy of genome sequencing and the development of bioinformatics tools
to analyze genomes for antibiotic resistance genes could enable the elucidation of new antibiotic targets.
Platforms to detect antibiotic resistance genes in genomes and metagenomes, such as DeepARG and
the Resistance Gene Identifier based on the Comprehensive Antibiotic Resistance Database, RGI CARD,
have been created [44,45].
2.2.2. BGC Activation and Engineering
Engineering known modular BGCs that assemble specific parts of existing antibiotics to yield
novel variants of well-known antimicrobials is an established approach, with the most notable recent
example being the production of a novel group of semi-synthetic rifamycins to fight multi-drug
resistant Mycobacterium tuberculosis [46]. However, the potential for secondary metabolite production
is estimated to be much larger than the number of biochemically characterized pathways. The genome
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sequences of many bacteria contain homologues of known antibiotic biosynthesis genes, such as those
encoding polyketide synthases and non-ribosomal peptide synthases. For example, the Actinomycetes,
Streptomyces coelicolor, and Sterptomyces avermitilis harbor, respectively, 20 and 30 operons for secondary
metabolites, although only a few are characterized [47,48]. Genome mining enables the identification
of silent or cryptic BGC which may not be expressed under standard laboratory cultures. Approaches
to activate silent or cryptic BGC responsible for producing novel metabolites have been reviewed
recently [49].
The major pathway specific approaches are the manipulation of regulatory genes controlling the
expression of specific pathways, the replacement of native promoters with constitutive ones, and the
use of heterologous expression systems. For example, the silent spectinabilin gene cluster has been
refactored by eliminating all the native regulatory control elements and replacing them with a series of
constitutive and inducible heterologous promoters, triggering the production of the previously silent
end product [50]. Two novel anthraquinone aminoglycosides, Gaudimycins D and E, were discovered
by inducing the expression of the pga gene cluster in Streptomyces sp. PGA64, using a promoter-reporter
system which identifies randomly generated mutants, wherein the target BGC has been activated [51].
A genome minimized Streptomyces strain has been constructed to facilitate the expression of antibiotic
BGC [52]. Methods to express large natural product BGC clusters in Streptomyces strains have been
recently optimized, and antibiotic production thereby achieved [53–55].
Pleiotropic approaches alter the expression of multiple genes, inducing global changes in the
regulation of specific metabolic pathways. The major pleiotropic strategies are the variation of growth
conditions and co-cultivation, epigenetic manipulation, engineering of global regulatory elements,
and the modification of the transcription and translation machinery. Varying the growth conditions
has been successfully used in many recent examples of antibiotic discovery. An older strategy is
upregulating the transcription and translation of cryptic BGC by selecting for mutations in the genes
encoding for RNA polymerase (RNAP) or ribosomal proteins. For example, mutations in the ribosomal
protein S12 in Streptomyces lividans induced the biosynthesis of the antibiotic actinorhodin [56]. A newer
approach is the chemical manipulation of the epigenome of fungi with inhibitors of histone deacetylase
or DNA methyltransferases in order to trigger the production of novel natural products. When
Penicillium citreonigrum was treated with the DNA methylase inhibitor 5-azacytidine, novel terpene and
polyketide natural products were produced [57]. Using an “old antibiotics for new” approach, adding
sub-lethal concentrations of clinical antibiotics was shown to activate otherwise unexpressed BGC
for novel antibiotics in strains of Burkholderia thailandensis [58,59]. Apart from undefined elicitors that
trigger antibiotic production, chemically defined molecules have been used as inducers of antibiotic
production [60–62]. QS signals were shown to be required to induce the biosynthesis of the antibiotic
pyrrolnitrin [63]. Compounds in chemical libraries or screens for blocking defined pathways have also
been utilized to elicit antibiotic production, for example by inhibiting fatty acid biosynthesis [61,62].
2.3. Novel Antimicrobial Sources
Researchers are increasingly finding therapeutics from sources long considered unlikely or
exotic. The use of plants used in traditional medicines, marine invertebrates, as well as insects and
vertebrate animals on land as potential sources for antimicrobials, is undergoing a revival. Recently,
an Entotheonella species residing in a marine sponge was found to synthesize more than ten different
antibiotic compounds [64]. Due to a long history of co-evolution, the bacterial symbionts of macroflora
and fauna could become a source of novel antibiotics [40]. Gut bacteria of the common pest, the
cotton leaf-worm, were shown to produce the peptide antibiotic mundticin [65]. Insect gut bacteria
might, thus, become a new source of antimicrobial peptides (AMP), with potential applications in
food additives and antimicrobial coatings. Amphibians, such as rainforest frogs, resist bacterial and
viral infections on their slimy skin and the activities of 14 antiviral peptides from different amphibians
were tested against HIV using human T-cell cultures [66]. An AMP was discovered in the blood of
the Komodo dragon Varanus komodoensis, a large reptile able to effectively resist the infection of open
Antibiotics 2019, 8, 8 6 of 34
wounds. The natural peptide was taken as a starting point to design a more potent synthetic peptide,
also having anti-biofilm activity [67]. Staphylococcus lugdunensis, a commensal of the human nasal
cavity, produces the antibiotic lugdunin [68]. A new Streptomycete, Streptomyces formicae, isolated from
the African fungus-growing plant-ant, was shown to produce 16 novel polyketide antibiotics called
“formicamycins” [69]. Insect-associated microbes also produce the antibiotics dentigerumycin [70]
and napthomycin K [71]. Current literature reports continue to describe endophytic fungal extracts
with antimicrobial activity [72–74]. Analysis of genomes of endophytic bacteria recently isolated from
Jamaican sugarcane using the antiSMASH platform reveals potential candidate BGC for antibiotics [75].
Fungi-fungi, bacteria-bacteria, and bacteria-fungi co-cultures produce secondary metabolites
not biosynthesized under standard laboratory conditions, and approximately half of the identified
metabolites induced during microbial co-cultivation, as opposed to monocultures, showed chemical
novelty [76]. Co-cultures are an increasingly important source of new antibiotics [76–78]. Cross-species
induction has been also achieved by exposing bacteria on the surface of marine algae or invertebrates
(epibiotic bacteria) or marine fungi to terrestrial bacteria [79–82]. Pestalone is a molecule produced
by cross-species induction and its total synthesis has been achieved and derivatives have been
synthesized [83]. Closthioamide is a novel sulphur-containing antibiotic active against pathogens,
including MRSA and vancomycin-resistant enterococci, produced by the anaerobe Clostridium
cellulolyticum when it is stimulated by sterile-filtered aqueous soil extracts [84]. Interspecies crosstalk
via chemical messengers between microbes occupying the same environment may lead to the
expression of BGCs not seen under laboratory conditions, even in well-known microorganisms.
For example, Aspergillus nidulans was shown to produce the compounds F-9775A and F-9775B when
co-cultured with soil actinobacteria; these compounds were initially isolated from Paecilomyces carneus
and were not known Aspergillus nidulans metabolites [85].
In nature, many growth factors are secreted by members of the microbial community surrounding
the organism one is seeking to isolate. Since the biochemistry of these factors is largely unknown, it is
unsurprising that traditional cultivation media mostly fail to produce colonies of previously uncultured
bacteria. Several recent platforms use microfluidic chambers to separate individual cells derived from
environmental samples. The bacteria are kept separate by means of capillary forces, while the growth
factors diffuse freely. Thus, “uncultivable” bacteria can grow unhindered in the chambers since their
natural environment is at least partly simulated. Microfluidic approaches succeeded in cultivating a
previously uncultivated strain, Eleftheria terrae, which produces the novel antibiotic teixobactin [16].
A high-throughput version of a diffusion chamber device, the I-chip platform, enables 15–40% of cells
to form colonies on agar after repeated inoculation into fresh chips [86]. A large proportion of the
colonies grown were novel and did not grow by traditional agar-plate methods. Culturing even a
fraction of the previously uncultured majority of bacteria could substantially expand the chemical
diversity of antibiotics.
Venoms (protein and peptide mixtures) from different animals, such as snakes, bees, scorpions,
spiders, and poison frogs, also have antibiotic activity. Melittin is a 26-amino acid bee venom peptide
that inhibits several pathogens, like Borrelia burgdorferi, Candida albicans, Mycoplasma hominis, and
Chlamydia trachomatis [87]. Snake venom metallo-proteinases (SVMPs) are capable of bactericidal
action by anionic site recognition and enzymatic degradation of phospholipid membranes. An
SVMP from Agkistrodon halys inhibits the growth of Gram-positive bacteria like Bacillus pseudomallei,
Proteus vulgaris, and Staphylococcus aureus [88]. Homodimeric phospholipase A2 is purified from
Bungarus faciatus snake venom (BFPA); the cationic BFPA likely disrupts the anionic Gram-positive
cell wall [89]. The antimicrobial activities of spider and scorpion venom peptides combined with
commercial antibiotics have been evaluated; one peptide, Css54, works synergistically with rifampicin
in killing rifampicin-resistant Staphylococcus aureus (55). Nanoparticles-venom toxin conjugates have
anticancer and immune-modulatory activities; similar nanoparticle-venom conjugates could perhaps
be employed as antibiotics.
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3. Novel Antimicrobial Molecules
Peptide chemistry and synthetic biology developed in a major way in recent years, expanding
the scope for novel therapeutics. Antibodies are receiving more attention due to rising antibiotic
resistance, while the development of inhibitors targeting efflux pumps, metal acquisition, and bacterial
conjugation, as well as antibiotic enhancers and photo-activated molecules, has created other ways to
tackle pathogens. Phage-based methods and breakthroughs, like CRISPR, may offer new routes to
contain infections. Figure 1 summarizes some of the most interesting classes of novel antimicrobials
that are emerging.
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3.1. Peptides and Peptide-Related Molecules
AMPs have served as antibiotics for decades now and new molecules continue to be developed.
The majority of peptide antibiotics are cationic, because the outer bacterial cell membranes are typically
rich in anionic lipids, unlike the zwitterionic eukaryotic cell membranes. Peptides encounter several
obstacles in their early development, including proteolytic instability, short in vivo half-life, solubility
issues, and poor bioavailability. Therefore, natural peptides are being used as scaffolds to design
more effective therapeutics. Many broad-spectrum anti-biofilm peptides have been identified in recent
years, since in vivo stability is less of an issue in wounds or epithelial surfaces [90]. The issues of
bioavailability and in vivo stability continue to hamper the direct administration of many peptides,
but their therapeutic properties could be improved by coupling to lipids, non-peptide antibiotics,
photosensitizers, immunoglobulins, etc. [91].
Target selectivity is often an advantage of peptides over other antimicrobials. A 2-pyridone
nonapeptide tested against Neisseria gonorrheae and Neisseria meningitidis in animal studies by PTC
Therapeutics, USA, showed that only the Neisseria species were susceptible, leaving Gram-positive
gut bacteria unaffected. Bactericidal action was suggested to occur via DNA-biosynthesis inhibition.
A pH-active peptide has been developed against Helicobacter pylori [92]. This AMP adopts a random
coil conformation at the physiological pH of the bloodstream or the intestines, while in the strongly
acidic medium of the stomach it assumes a helical conformation containing positive charges, which
destabilize the membranes of the pathogen. This strategy enables selective targeting of the pathogen,
while leaving the larger gastrointestinal tract microbial community intact.
Lipopeptides contain at least one lipid chain attached to the peptide head groups and are chiefly
produced by bacteria to mediate competition with other bacteria, fungi, and viruses. They differ
from other types of peptides due to the formation of self-assembled nanostructures contingent
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upon the intermolecular interactions between peptide molecules and the balance of hydrophilic
and lipophilic groups. Modified derivatives of the antibiotic polymyxin containing substitutions to
the cyclic heptapeptide and a fatty acid moiety were reported to be more potent than polymyxin
itself by Cantab Anti-infectives, UK [93]. The lipopeptide Daptomycin (Cubicin™) [94] is used to
treat systemic life-threatening Gram-positive bacterial infections, including multiple drug-resistant
cases [95]. It alters the curvature of the bacterial cell membrane by aggregation, creating holes that leak
ions. Rapid depolarization ensues, resulting in a loss of membrane potential leading to inhibition of
protein, DNA, and RNA synthesis and killing the bacteria [96]. Surotomycin is a cyclic bactericidal
peptide [97], which has been evaluated comparatively versus vancomycin and metronidazole for
over 1000 intestinal strains [98]. It demonstrated lower recurrent rates and superior sustained clinical
response rates for Clostridium difficile infections compared to vancomycin in phase 3 clinical trials [99].
Lantibiotics are peptides produced by Gram-positive bacteria containing rare post-translationally
modified thioether amino acids, such as lanthionine (Lan) and methyllanthionine (MeLan); their
biosynthesis, engineering, and mechanisms of action are reviewed elsewhere [100]. They are effective
at low nanomolar concentrations, since Lan and MeLan induce the formation of intramolecular cyclic
structures, offering resistance against bacterial proteases. Apart from the lanthionines, 17 other
non-canonical amino acids, including didehydroalanine (Dha), didehydrobutyrine (Dhb), D-alanine,
S-aminovinyl cysteine, lysinoalanine, and oxobutyrate, are found in lantibiotics. Due to their multiple
modes of action, no notable resistance against lantibiotics has developed over decades. However,
some bacterial strains are congenitally resistant against the prominent lantibiotic nisin [101]. Recently,
two of the five lanthionine rings of nisin (rings D and E) were identified as playing a “fostering
role” in the cleavage of nisin by the nisin resistance protein of Streptococcus agalactiae, paving the
way for the synthesis of non-hydrolysable nisin analogues [102]. Bioengineering efforts have made it
possible to modify the lantibiotic producing genes to create newer lantibiotic variants [103]. The LetM
in vitro system was used to generate thioether and didehydro analogues of known non-lantibiotic
peptides [104]. Pioneering in vivo studies enabled the introduction of dehydrated residues and
thioether rings into non-lantibiotic peptides in Lactococcus lactis [105,106].
Glycoconjugate vaccines are carbohydrate antigens linked with proteins and were earlier created
by randomly conjugating polysaccharides to basic or acidic residues on the surface of proteins.
Mostly capsular polysaccharides were used, but glycoconjugation has been expanded to include
O-antigens, exopolysaccharides, and teichoic acids [107]. Classical vaccines were obtained via isolation
of polysaccharides directly from pathogens, but site-selective conjugations, protein modifications
using unnatural amino acids and chemical or enzymatic modifications of native amino acids, and the
bioengineering of carbohydrates (glycoengineering) are beginning to redefine this field [108]. Chemists
can now also synthesize rare deoxy sugars found in bacterial cell surfaces, but not in humans, which
may facilitate the development of new glycoconjugate vaccines [109].
All-D versions of peptides have been created by retroinversion (reversing the primary sequence
and changing its amino acids to D-versions). However, this strategy is ineffective for helical peptides,
since the direction of helix rotation does not change, leading to differences in orientation of particular
groups with respect to the corresponding natural peptides. A new computational approach changes
this situation by generating a D-version of every protein structure deposited in the PDB database [110].
After the D-PDB was thus created, all the D-protein α-helices were extracted, generating over 2.8
million files. Known protein-drug interactions were used to screen for D-helices that bound similarly
to targets in silico to known protein and peptide drugs. Short D-strands created by retroinversion were
used to link D-helices into D-analogues of known therapeutic peptides. This design strategy could
enable the creation of novel completely synthetic AMP.
A unique post-translational modification arising out of a previously unknown non-canonical
protein-splicing reaction was shown to introduce β-amino acids into proteins [111]. The β-amino
acids are structurally distinct from the α-amino acids that occur in natural peptides and proteins, in
that they contain two carbons between the amino and carbonyl groups. The enzyme PlpXY catalyzes
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this reaction by removing tyramine from a tyrosine-glycine pair. It splices the gap by joining the
orphan carbonyl group with the carbonyl group of the adjacent amino acid, thereby converting the
adjacent amino acid into its α-keto-β-amino form. The β-peptides are resistant to proteases in the body,
apart from providing an extra keto group as a chemical handle for further modification. Both these
features make the PlpXY system an attractive means to potentially synthesize novel AMP. Recent years
saw the expanding repertoire of non-canonical amino acids incorporated into proteins produced by
ribosomes, which has been covered in detail elsewhere [112]. Rather than modifying t-RNAs, codons,
and ribosomes, the number of bases usable by DNA to encode proteins has been augmented from
four to six [113]. The two artificial bases, dNaM and dTPT3, undergo complementary base pairing not
by hydrogen bonding, but by hydrophobic stacking. The expanded genetic code was inserted into
Escherichia coli, whereby unnatural proteins could be produced via translation. This breakthrough
in semi-synthetic genetic code expansion could soon enable the production of designer antibiotic
peptides and new vaccines.
3.2. Antibodies
The development of pathogen-specific monoclonal antibodies (mAb) is an emerging and highly
promising area in infectious disease research. Passive immunization using serum therapy was used for
the treatment of bacterial infections well before the discovery and development of antibiotics. However,
due to the great success of antibiotics, the therapeutic potential of antibodies, the key molecular
players of the adaptive immune system, has not been exploited fully. The successes of mAb-based
therapies for cancers and autoimmune diseases and the increasing cases of antibiotic resistance have
led many researchers to revisit this overlooked avenue of research. Currently, Palivizumab (brand
name: Synagis), the only mAb-based antimicrobial on the market, is a humanized mAb approved
against prophylaxis of respiratory syncytial viral (RSV) infection in neonates. Unlike antibiotics,
mAb can be given prophylactically and have great scope in protecting vulnerable patients, such as
those undergoing organ transplantations, bone-marrow transplantations, or in intensive care units.
One of the key advantages of mAb over antibiotics is their exquisite target specificity and several
are currently in the advanced developmental stages [114]. Thus, mAb could offer superior potency
without adversely affecting the beneficial host microflora, while their high target specificity may
provide less scope for selecting resistant strains.
Unlike polyclonal antibodies, mAb are structurally uniform and well-defined, offering excellent
sample-to-sample consistency and superior on-target activity. However, polyclonal antibodies can
simultaneously target multiple epitopes by different isotypes, but mAb cannot. This limitation could be
overcome by administering a cocktail of mAb, targeting not only different epitopes of the same antigen
but different antigens. The target affinity of each individual mAb against its antigen epitope is higher
than that of a polyclonal antibody and better protection from the pathogen would be accomplished. The
production of human and humanized mAb has been achieved, whereby the risks of immunogenicity
and toxicity are significantly lower than with conventional mAb. In a noteworthy example, Rossmann
and co-workers developed a method for selecting B-cell producing antibodies with high opsonic killing
against Enterococcus faecalis 12030 in healthy individuals, and produced fully human mAbs offering
in vivo protection against many multi-resistant Gram-positive bacteria [115].
Existing diversity among bacterial strains and the rapid evolution of viruses that can modify their
surface proteins may lead to weak binding of antibodies, and leading to failure to provide protection.
However, antibodies can be altered with molecular biology methods, and these engineered antibodies
could bind multiple targets rather than just one, thereby increasing their potency. Recently, an antibody
that could bind three different targets on the HIV-1 envelope, namely the CD4 binding site, the V1V2
glycan site, and the MPER (membrane proximal external region) simultaneously, was reported [116].
These broadly neutralizing antibodies (bnAb) performed better than previously known bnAb against
a mixture of simian-HIV strains in non-human primates. Multi-specific engineered antibodies could
thus have wider applications in antimicrobial therapy.
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3.3. Phage-Based Strategies and CRISPR
Virulence reduction in bacteriophage resistant strains is known in multiple pathogenic
bacteria [117]. It is a mechanism that bacteria cannot easily evade, since the same phages attenuate
virulence both in natural environmental reservoirs and in humans. The ICP-1 phage of Vibrio cholerae
targets the O1 surface antigen, which is important in human infections. V. cholerae usually evades this
phage by mutations in the O1 antigen [118]. Similarly, the ICP-2 phage targets the outer membrane
porin OmpU, which is also important in human infections. However, the ability to evade the ICP-1
and ICP-2 phages via mutations in the O1 antigen and the OmpU porin, respectively, compromises
the ability of V. cholerae cells to survive the innate defenses of the human host. Similarly, 50–70%
attenuation of virulence has been reported in phage-resistant P. aeruginosa, which harbor mutations in
the O1 antigen and pilus [119]. Not all phage species are beneficial and they can incorporate genes for
toxins and virulence factors into the genomes of bacteria. They can stay dormant for prolonged periods
in bacterial cells, revive and infect other bacteria, spreading the virulence genes they carry in the
process. Recently, a study of Salmonella enterica infections in mice reported that the host inflammatory
response triggered the spreading of phage-based virulence among the bacteria [120]. Vaccination
using engineered Salmonella that could not induce inflammation were shown to dramatically reduce
the transmission of phage-based virulence between donor and acceptor strains, suggesting that
suppressing host tissue inflammation is a way to contain such infections. Recent advances in the
synthetic biology of phages make it possible to swap the tail domains of phages, thereby changing
their host specificity [121]. Endolysins are enzymes secreted by bacteriophages and engineering them
produces bactericidal “artilysins” [122]. These studies could stimulate the development of more
generic phage-based approaches for controlling infections.
CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 was originally
discovered in bacteria, where it is a form of adaptive immunity against bacteriophages [123]. RNA
guides the Cas9 endonuclease to the phage DNA, which is cleaved and degraded. Following this
discovery, other scientists repurposed CRISPR/Cas9 as a genome editing tool [124,125]. Soon, the
self-targeting-induced cytotoxicity of CRISPR-Cas systems was reported, and researchers realized
that the system could be used to immunize bacterial cells against plasmids containing multi-drug
resistance genes [126–128]. CRISPR interference was shown to prevent the acquisition of virulence
in vivo [129]. Cas9 was reprogrammed such that virulence genes could be selectively targeted with
CRISPR-Cas9, enabling sequence specific killing of virulent strains, while leaving non-virulent ones
of the same bacterium unaffected [129,130]. Soon afterwards, CRISPR-Cas systems were proposed
as programmable antimicrobials; both endogenous and heterologous systems could selectively kill
pathogenic bacteria, regardless of the target sequence [131]. While each engineered CRISPR-Cas system
would be specific for one particular sequence, CRISPR itself could be broadly effective against any
pathogenic bacterium.
3.4. Miscellaneous Antimicrobials
With increased understanding of the biology of specific diseases, new therapeutic enzymes,
inhibitors, and vaccines specific to each pathogen may be produced. For example, the specific
depolymerase EnvD [132], extracted from the soil bacterium, Pusillimonas noertemannii BS8, strips
Bacilllus anthracis of its protective polypeptide capsule in the vegetative state, and enables mice to
survive the inhalation of B. anthracis spores. Sugar-based bactericides have also been successful against
Bacillus anthracis and Bacillus cereus, which often resist ciprofloxacin [133]. Species-specific compounds
may be found in commercial compound libraries of potential antibiotics, even though they may have
failed tests for broad-spectrum antibiotic activity. Therefore, repurposing old molecules from high
throughput screening efforts may also be beneficial. Another strategy to limit microbial infection is to
exploit the differences between the host and microbes in the structures of certain enzymes. Recently,
a specific inhibitor, dubbed “Pseudouridimycin”, which binds to the active site of bacterial RNA
polymerase, but not the human RNA polymerases, was reported [134]. Pseudouridimycin resembles
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the natural substrates of bacterial RNA polymerase and is expected to be effective against a range of
drug resistant pathogens.
The new field of photopharmocology involves the synthesis of “smart drugs”, whose activity
can be controlled by light. The incorporation of “photo-switch” structures into therapeutic
molecules allows for the remote-control of their properties, an approach well-suited to reduce the
unintended environmental effects of antibiotics contributing to resistance. Photo-activated analogues
of ciprofloxacin and gramicidin S were reported, with the former study describing a 50-fold increase
in activity with light-activation [135,136]. Earlier studies were confined to molecules activated
by UV light, which is toxic to living cells and does not penetrate tissue easily. However, recent
breakthroughs enabled the use of visible light of different wavelengths for tuning the bioactivity of
various photo-switchable trimethoprim analogues tested against E. coli [137].
Metal acquisition is crucial for pathogenic bacteria during infections, since the host imposes
metal limitation as a form of “nutritional immunity” [138]. Bacteria sequester not only iron, but
also manganese and zinc [139,140]. Synthetic siderophores are structural analogues of natural
small molecules produced by bacteria mainly to chelate iron and used in quorum sensing, and are
well-tolerated by animal hosts with MIC (minimum inhibitory concentration) values in the nanomolar
range. Tethering synthetic siderophores to regular antibiotics could be a broad strategy against
Gram-negative bacteria. An ampicillin-siderophore conjugate was shown to kill P. aeruginosa, while a
cephalosporin-siderophore conjugate could kill Acinetobacter baumannii [141]. Due to their structural
similarity with natural bacterial molecules, siderophore analogues are thought to evade the efflux
pumps that render common antibiotics useless.
In efforts to stem the rising tide of antibiotic resistance, small molecule inhibitors for multidrug
efflux pumps and the bacterial conjugation machinery are being developed [142,143]. Efflux pump
inhibitors (EPI) face the formidable obstacle that the multi-drug resistance (MDR) pumps of pathogens
bind a large variety of chemically unrelated compounds. Nevertheless, efforts are on to identify
the natural substrates of the MDR pumps, and a few generalizations could be made. Small polar
compounds penetrated the MDR pumps easily, while zwitterions are also effective, since amphipathic
cations are the assumed natural substrates. The inclusion of non-biological elements such as fluorine
or boron increased the potency. A new, boron-containing class of antibiotic compounds with activity
against Gram-negative bacteria was reported recently [144]. Bioassay-guided and high throughput
strategies yielded EPI from plants and fungi, and synthetic analogues are known; EPI may perform
better combined with other antimicrobials than alone [143,145].
Plasmid-borne resistance genes can be spread by bacterial conjugation, and the search for specific
conjugation inhibitors (COINs) that block plasmid transfer is ongoing [142]. First, generation inhibitors
were rather unspecific, having other confounding effects. The compound 2-hexadecynoic acid
(2-HDA) is a simple compound readily accessible via chemical synthesis, which specifically inhibits
conjugation in a broad range of donor cells [146]. Synthetic unsaturated fatty acid derivatives, in
particular, are being used in efforts to prevent the transmission of antibiotic resistance among complex
bacterial populations [147]. Targeting the bacterial assembly protein T4SS with small molecules
was reported [148]. Other targets for COINs include the conjugative pilus and the relaxase protein,
which initiates conjugation when the plasmid DNA is nicked. Luminescence-based high throughput
conjugation assays are being applied to identify COINs in compound libraries [147].
Multi-hybrid antibiotics are large molecules containing structural domains from more than one
antibiotic class. The best-known example is simocyclinone, which consists of distinct cyclic polyketide,
deoxy sugar, polyene, and halogenated aminocoumarin moieties [149]. Using just 12 building blocks
and one coupling reaction, about 75% of known polyene motifs could be synthesized [150]. Iterative
biomimetic methods for polyketide synthesis have also emerged [151–153]. BGC-like modularity
may soon be commonplace in natural product synthesis. Recent advances in synthetic chemistry
have widened the range of sugar nucleotides and deoxy sugars accessible [154,155]. Together, these
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developments have created opportunities to create synthetic antibiotics in known classes as also
synthetic and semi-synthetic multi-hybrid antibiotics by assembling separate domains.
Simple molecules like bicarbonate (a widespread buffer in the human body) are being studied for
modulating the effects of antibiotics. Bicarbonate decreases the pH gradient across the cell membranes
of bacteria, enhancing the uptake of aminoglycosides, but suppresses that of tetracyclines [156]. The
bicarbonate effect is specific to the mechanism of action of each antibiotic. In response to a drop
in the pH caused by bicarbonate, cells transport more ions across the membrane. This increased
charge distribution enables aminoglycosides to cross the membrane effectively, enhancing their effects.
Bicarbonate also ramped up the effectiveness of the natural defense peptide indolicidin 100-fold in an
assay against E. coli [156]. Combining the antibiotic minocycline with non-antibiotic drugs enhanced
therapeutic efficacy, with some success against multi-drug resistant strains [157]. More widespread
use of enhancers might extend the clinical lifetime of existing antibiotics.
4. Antimicrobial Materials
Novel materials and technologies represent antibiotic-free ways to prevent microbial infections,
but can also deliver antibiotics, as summarized in Table 2.
Table 2. Current antimicrobial materials and technologies for infectious disease prevention, in
preclinical development, and as vehicles for antibiotic delivery.
Prevention Preclinical Antibiotic Delivery
Graphene and silver-based nanomaterials
Organic-inorganic hybrid nanoparticles
Microbots for water treatment
Phage-patterned nanoparticles Silica nanoparticlesNanoparticle-liposome conjugates
Engineered spider silk Electrochemical H2O2 generation
Hybrid bacteria-nanoparticle
swimmers
4.1. Nanomaterials
The rapid growth of nanotechnology in the recent decades has opened up new possibilities
for controlling microbial infection based on novel materials. Nanoparticles have been used in a
variety of drug delivery systems in recent years. A recent study reported that silica nanoparticles
containing peppermint oil and cinnamaldehyde could penetrate biofilms and kill drug-resistant
bacteria [158]. A 99.9% kill rate with this method has been reported for the biofilm pathogens
P. aeruginosa, E. coli, Enterobacter cloacae, and S. aureus. The acidic milieu of biofilms breaks down
the silica of the nanoparticles, releasing the antibiotics within. This approach has been shown to
work in cell cultures, and the main applications are expected to be disinfection and wound cleaning.
Cinnamaldehyde triggers the activity of fibroblasts, which are immune cells involved in wound healing.
This is significant since biofilms are often resistant to antibiotic penetration.
Graphite, graphene, graphene oxide, and reduced graphene oxide were shown to have broad
spectrum antimicrobial activities against bacteria and fungi [159]. Mixtures of graphene oxide with
other simple substances have also been used for the same purpose. Graphene oxide kills bacteria by
disrupting membranes as well as oxidation stress, whereas reduced graphene oxide traps bacteria [159].
The medical properties of silver and silver compounds have been known for 2000 years, but the
antimicrobial activity of silver nanoparticles (size range 1–100 nm) has only been recognized since
2004 [160]. Silver nanoparticles can enhance the effect of commonly used antibiotics [161]. They have
been used in wound dressings and commercial antimicrobial socks. Recently, silver nanoparticles
were shown to kill the chlorine-resistant apicomplexan parasite Cryptosporidium parvum [162]. Many
pathogens have become resistant to conventional disinfectants, necessitating increasing dosage and
mixtures of disinfectants that may produce harmful by-products. Therefore, the incorporation of silver
nanoparticles into filtration or water purification systems could prevent several types of water-borne
illnesses. A novel example has been the use of multi-layered “Janus microbots”, containing silver
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nanoparticles as the disinfectant, a magnesium layer to help propel the microbots in water (via
hydrogen evolution), and an iron layer to enable remote guidance via magnetism [163]. The microbots
(along with the dead bacteria) can simply be collected after disinfection, thereby cleaning the water in
one step and leaving no contaminants behind.
Nanoscale organic-inorganic hybrid particles, called “nanoflowers”, which are loaded with the
enzymes, glucose oxidase (causing a pH change upon consuming glucose), and ConA (which binds the
lipopolysaccharide O-antigen), have enabled the detection of food pathogens, including E. coli O157:H7,
Salmonella, and Listeria monocytogenes, using simple pH meters [164]. While the application of modified
viruses and different types of coated nanoparticles as antimicrobials has emerged in recent years, novel
bacteriophage-shaped polymer nanoparticles have been shown to kill pathogenic bacteria, including
some antibiotic resistant strains, such as multi-drug resistant P. aeruginosa, while leaving human cells
unharmed [165]. Apparently, the particles’ geometry is the key property, enabling them to rupture
the more curved bacterial cell membranes while not affecting the relatively flat lipid membranes of
human cells. Other nanomaterials, such as chitosan-modified gold nanoparticles, can be conjugated
with liposomes encapsulating antibiotics. Antibiotic release from liposome-conjugates triggered by
bacterial toxins has been demonstrated [166]. When the conjugates encounter bacteria that secrete
pore-forming toxins, the toxins insert into the liposomes, pores are formed, and the antibiotic within
escapes. This mode of antibiotic release is more selective than unrestricted release from liposomes
under physiological conditions.
4.2. Materials and Techniques Targeting Biofilms
Biofilms contain a tough protective polysaccharide layer, conferring resistance to antibiotics. They
form on the surface of medical implants and inside wounds. Recently several biomedical firms in
Germany and the United States have been developing spider silk protein for coating catheter implants
and medical devices. The build-up of bacteria on these device surfaces is prevented by spider silk,
which could lead to significant savings for patients. Recombinant spider silk has been used in many
studies and recent research also demonstrated the possibility of conjugating organic ligands to spider
silk, creating variants with fluorescent or antibiotic properties using “click” chemistry [167]. It is
possible that commercial antibiotic dressings made of spider silk will be available within the next few
years, especially for treating conditions such as diabetic ulcers.
Biofilm removal is a priority in the treatment of wounds, since the biofilm delays the healing
process, resulting in a chronic wound infection. Electrical stimulation (ES) was originally used a
century ago for wound treatment and has been applied in dermatology [168–171]. ES can eliminate
biofilms from infected wound surfaces, enhancing wound healing. However, it was not widely applied
because knowledge of the antibacterial mechanisms involved and standardized applications were
lacking [168–173]. However, the rise in antibiotic resistance led renewed interest in ES. In a recent study,
bacteria in biofilms were effectively killed by using electricity to release small amounts of hydrogen
peroxide continuously via a conductive carbon fabric [174]. Electrochemical H2O2 generation thus
represents a novel antibiotic-free way to keep wounds free from bacterial infection. Another strategy
to tackle biofilms employs magnetotactic Magnetospirillum bacteria as swimmers delivering antibiotics
into them [175]. The swimmers consist of mesoporous silica tubes filled with antibiotics, tethered to
the magnetic bacteria. Under the influence of an external magnetic field, the swimmers enter the low
oxygen environment of E. coli biofilms and the low pH of the biofilms triggered the breakdown of the
silica microtubes, releasing the antibiotic. Although host immune reactions could destroy them, these
hybrid swimmers could be explored further.
5. Technological Advancements in Diagnostics and Screening
Technologies for screening and diagnostics relevant to infectious diseases are exploding in the
commercial sector. An overview of a few prominent examples is presented in Table 3.
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Table 3. Major new technologies in infectious disease diagnostics.
Monitoring Technology Types Direct in-Sample Methods Point-of-Care Devices
Mass spectrometry-based Magnetic resonance-based Microfluidic blood serum separator
Automated imaging Smarticles Portable influenza tester
Microfluidics-based DNA sequencing-based -
Label-based - -
5.1. Infection Monitoring Technologies
Functional markers of antibiotic resistance that can be followed to identify pathogens are enzymes
that directly degrade or modify antibiotics, mechanisms blocking antibiotics from reaching their
targets, key resistance factors (specific genes and proteins), changes in intracellular composition or
secreted products, and changes in cellular expression induced by antibiotics. Many newer methods
offer results of antibiotic susceptibility testing in 2–6 hours instead of the days needed for traditional
agar-based methods. Changes in morphology or other parameters can be monitored continuously in
real time, an especially useful approach for well-known pathogens. With recent improvements to mass
spectrometry techniques, such as MALDI-TOF MS and ESI-MS, and next-generation MS methods,
new opportunities to track microbial diseases have arisen. MS-based strategies may involve tracking
changes in metabolism through the use of stable isotope probes, such as amino acids. The detection
of antibiotic response in real time, DNA sequencing based on MS technologies, the detection and
quantification of metabolite profiles of growing cells, the direct detection of virulence factors, and
following the penetration of antibiotics into cells have been facilitated by recent platforms. Other
methods combine chromatography with mass spectrometry, such as GC-MS for metabolomics. One
important development was the introduction of an MS-based spectral imaging system, which enables
three-dimensional study of cellular contents at the nanoscale [176].
Monitoring the growth of pathogens in real time using microscopy has been important in
identifying and treating infections. Manual monitoring is tricky and time consuming, and therefore,
automated monitoring is growing. Automated digital microscopy in real time on agar media was
introduced recently by Accelerate/QuantaMatrix, while real-time liquid phase microscopy in an ELISA
layout was introduced by Biocell/Philips. Other than new-generation microscopes, devices such as a
laser scatter device, which uses immobilized bacteria and detects morphological changes in single cells
(BacterioScan Inc.), and a Fourier transform Infrared (FT-IR) spectrometer, which detects phenotypic
changes upon interaction of cells and antibiotics in about 10 minutes (Spectromics Ltd, Manchester,
UK), have entered the market.
A microfluidics device that measures changes in electrical conductivity in droplets containing
bacteria was able to determine if they were alive or dead [177]. This is interesting, since the method
does not depend on cell type or concentration, and is “label-free”. Further development is expected to
lead to array-format electrical sensors for lab-on-a chip applications. Microfluidics has also been used
in combination with acoustic tweezers to sort cells according to their response to drug candidates [178].
Another recent development is a chip which enables co-cultivation of gut microbes and epithelial
cells of the human intestines [179]. Such “Gut-on-a-chip” technologies help simulate the human
gut in health and disease, contributing to better understanding and future therapeutic interventions.
Microfluidics for monitoring antibiotic resistance is also a rapidly advancing field [180]. Microfluidic
chips for single cell sequencing of uncultured microbes have emerged, which makes high-throughput
culturing and genome sequencing of unknown microbes possible [181].
The infection of implants is a major issue affecting the outcome of surgery, especially for
orthopedic or trauma patients. Implants may also loosen aseptically due to mechanical causes or due
to septic infections, but traditional radiology and biopsy culture-based methods cannot distinguish
between the two scenarios. An AMP called UBI was tethered to a hybrid label containing both
a fluorescent group and a radioactive isotope, and it was demonstrated that the AMP-conjugate
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selectively accumulated at the site of bacterial infections [182]. Distinguishing septic infection from
inflammation has thus been enabled by a specific labelling approach.
5.2. Direct in-Sample Technologies
The need for enrichment, culture, or sample preparation is a major reason for the delay between
obtaining clinical samples and analyzing them. Therefore, directly in-sample detection methods
for pathogens were launched. In a magnetic resonance-based platform introduced by T2 MR,
proprietary particles are coated with specific binding agents. Encountering a target, the particles
bind to and cluster around it, modifying the arrangement of water molecules in that sample and
thereby changing the magnetic resonance signal. The change in the signal correlates with the
absence, presence, or concentration of the target, tolerating interferences likely present in bodily
fluids. Testing for amplified DNA probes attached to particles using magnetic resonance spectra
combined with PCR; this system can deliver results in about 2 hours. The ability to analyze antibiotic
susceptibility or identify multi-drug resistance without further processing of clinical samples is
advantageous. Geneweave/Roche launched the “Smarticles” technology based on the delivery of
“smart particles” with specific probes. Upon binding of targets with the probes, these “Smarticles”
generate luciferase-mediated fluorescence in live cells directly in clinical samples, enabling rapid
automated analysis. Lifescale Analytics introduced a device which measures changes in cell mass
directly on clinical specimens. The Oxford Nanopore MinION sequencer offers portability, speed,
and relatively long read lengths. For example, MinION-based analysis of urine samples generated
data enabling the direct detection of pathogens four times faster than traditional culture-based
methods [183].
5.3. Point-of-Care Devices
The development of integrated diagnostic work-flows designed for the Point-of-Care (the doctor’s
office or health center), rather than specialized medical labs, promises to reduce the delay between
sample collection and analysis. Speeding up diagnosis could help the patient before the disease
proliferates, an important consideration for tackling fast-progressing infections, epidemics, or infections
in remote or low-income settings with unreliable power and transport facilities. Recently, the
fabrication of a microfluidic device able to separate serum from cells in a single drop of blood was
reported [184]. PCR amplification of DNA from the samples could be performed in situ, since the
necessary reagents were patterned into wells present in the device. Heating the whole assembly in an
oven enabled the detection of viral RNA or bacterial DNA in the range of 101–105 copies/µL. A rapid
and inexpensive assay to distinguish between influenza and bacterial infections has been recently
developed [185]. The test uses an artificial sialic acid conjugate of galactose that is cleaved only by
viral, but not bacterial, neuraminidases, and the released galactose can be detected by a common
hand-held glucose meter. The integration of new biochemical tests with existing medical devices and
emerging Point-of-Care devices could potentially revolutionize the field of infection diagnostics.
6. Ecological Management
It has become clear in recent years that the resident microbiome is critical to human health. Rather
than attacking pathogens directly with drugs, ameliorating the damage to the host via microbiome
engineering might be a preferable strategy for countering infectious diseases. This could reduce the
need for antibiotics as a broad catch-all strategy for countering microbial disease. In order to design
future interventions into the microbiome, ecological interactions between members of microbiomes
and host-microbiome interactions need to be studied and understood.
6.1. Probiotics, Synbiotics and Prebiotics
Two approaches involving microbiome-related interventions are worth mentioning, namely
probiotics and prebiotics. The Nobel laureate Élie Metchnikoff had in 1907 already suggested that
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"the dependence of the intestinal microbes on the food makes it possible to adopt measures to modify
the flora in our bodies and to replace the harmful microbes by useful microbes” [186]. Currently,
“probiotic” is the designation for microorganisms, which upon ingestion are beneficial for humans or
domestic animals [187,188]. Several reviews have been written on the subject and many commercial
food products and supplements are being sold as purported “probiotics”. The benefits of Lactobacillus
and Bifidobacterium species have been researched intensively. Lesser known strains include Bacillus
clausii Strain O/C, which secretes factors inhibiting the cytotoxic effects of the toxins from Clostridium
difficile and Bacillus cereus [189]. Clostridium tyrobutyricum was shown to be protective against induced
ulcerative colitis in mice [190].
A prebiotic is defined as a “selectively fermented ingredient that allows specific changes, both
in the composition and activity in the gastrointestinal microflora that confers benefits upon the
host’s well-being and health” [191,192]. Synergistic combinations of probiotics and prebiotics are
called synbiotics [191]. Prebiotics commonly exhibit the properties of resistance to gastric acid,
hydrolytic mammalian enzymes, and absorption in the gastrointestinal tract, as well as fermentation
by the microbes of the intestine, and specific stimulation of bacterial activity and growth in the
intestines, leading to the maintenance of host health and well-being [192,193]. Presently, a few
categories of compounds considered to satisfy the above definition of prebiotics include fructo- and
galacto-oligosaccharides, lactulose, and indigestible carbohydrates. The indigestible carbohydrates
include inulin, pectins, gums, cellulose, and hemicellulose among the larger polysaccharides,
and oligosaccharides, sugars, and alcohols, which cannot be absorbed by the host intestines.
Fructo-oligosaccharides and inulin are hydrolyzed by Bifidobacteria and stimulate their growth, which
in turn contributes to intestinal homeostasis and inhibits the growth of pathogens [194–196].
Short chain fatty acids (SCFA), for example, acetic acid, propionic acid, and butyric acid, are
produced as the end products of carbohydrate and amino acid catabolism. Epithelial cells in the colon
derive energy from gut microbes performing carbohydrate fermentation [197]. SCFA are able to induce
apoptosis (programmed cell death), lowering the risk of developing not only gastrointestinal disorders,
but also cardiovascular diseases and cancers [198,199]. Butyrate production by resident Clostridium
species in the gut induces colonic regulatory T-cells in the host, suppressing its immune reactions,
including the inflammation of the intestinal mucosa, which is implicated in many diseases [200]. More
research into simple small molecules able to modulate the microbiome, whether or not strictly prebiotic,
may prove fruitful.
6.2. Understanding Ecological Interactions in Health and Disease
6.2.1. Host-Microbiome Interactions
Members of the resident microbiome can switch their lifestyle, from beneficial or just commensal
to pathogenic, sometimes triggered through relocation of a given microbial species from its normal
niche to another where it is normally absent. Injury or trauma, stress, or reduced immunity of the
host can also trigger the switch. Bacteroides thetaiotaomicron is a beneficial member of the human gut
microbiome, which ferments carbohydrates and stimulates host immune development. However,
migration to other organs, such as the brain, lungs, or liver, causes it to become pathogenic [201].
Streptococcus pneumoniae is a commensal of the human respiratory system, where it produces hydrogen
peroxide to kill competing bacteria. In the bloodstream, lungs, and inner ear, it causes infection by
secreting a pore forming toxin [202]. S. aureus is a normal resident of human skin, and nasal cavity
which can cause systemic sepsis if it enters the bloodstream [203].
The interplay between human hosts and bacterial pathogens is well-studied. However, in
many cases, an important role could be played by the bacterial community in the development
of infectious disease. Antibiotic treatments often induce diarrhea due to the disturbances to the
indigenous microflora of the gut. The major mechanism is proposed to be the alteration of intestinal
barrier function and reduced resistance to pathogens and altered metabolism of SCFAs and bile
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acids [204]. Probiotics, including the yeast Saccharomyces boulardii and many Lactobacilli, such as
Lactobacillus acidophilus, Lactobacillus rhamnosus GG, Lactobacillus delbruckii, and Lactobacillus fermentum,
effectively reduce the occurrence of antibiotic-induced diarrhea [205]. Of particular concern is the
increased vulnerability of patients to Clostridium difficile infections followed prolonged antibiotic
administration [206]. Eradication of other members of the gut microbiome, which are normally
protective, may enable Clostridium difficile to thrive. This “niche vacation” hypothesis is further
supported by the fact that Clostridium difficile infections were ameliorated with species present in
the fecal pellets from healthy volunteers used in “faucal transplant therapy” [207,208]. The material
used for the therapy later became available in capsule form [209]. Prior to bloodstream infection
by vancomycin-resistant Enterococcus (VRE) species in immuno-compromised patients, Lactobacilli
and related genera in the gut are replaced by Clostridia and Enterobacteriaceae [210]. Not surprisingly,
some VRE patients respond well to fecal transplants, with the beneficial microbe being identified
as a Barnesiella species [211]. Even two different strains of the same species can interact; horizontal
gene transfers conferring plasmid-borne resistance to multiple antibiotics were already reported by
1974 [212]. However, in the context of the human microbiome, antibiotic-sensitive commensal bacteria
can also compete out their resistant peers of the same species, as reported for Enterobacter faecium [213].
Interestingly it was reported that commensal Entercoccus faecalis strains turned the mobile genetic
elements of the vancomycin-resistant Enterococcus faecalis V583 strain against the latter, effectively
killing them [214].
In the ecological sense, infection can happen when new niches are opened up due to direct
damage to the host itself, or when existing niches are emptied of beneficial bacteria, creating a
colonization opportunity for pathogens. “Colonization resistance” is the protective effect of the
microbial community composition against pathogens [215]. Direct antagonism between two species
was reported in a study of mice; the Escherichia coli strain Nissle 1917 could prevent Salmonella
typhimurium infection by sequestering iron [216]. Vibrio cholerae contains several genes enabling it
to resist the Type VI secretion systems of many normal intestinal microbes [217]. Several members
of the microbiota are capable of inhibiting colonization by Vibrio cholerae, and recovery from cholera
involves recolonization by indigenous “healthy bacteria” [61]. Subjects with a certain skin microbiome
composition were resistant to a sexually transmitted disease, and knowing the skin microbiome
composition could be a strategy to identify people at risk of infection [218]. There are differences
between single and mixed infections, due to cooperative and competitive interactions between bacteria
involved in quorum sensing [219]. In synthetic media, Pseudomonas aeruginosa cells with mutations in
the lasR gene are out-competed by the wild type, since the former do not respond to quorum sensing.
However, in mixed culture, lasR mutants of Pseudomonas aeruginosa become “social cheaters”, gaining
an advantage by exploiting the exoprotease production of wild-type cells [219,220]. This could explain
the observation that lasR and other quorum sensing mutants persist in infections, even though “loss of
function” mutations may be deleterious.
6.2.2. Inter-Microbial Interactions
Bacteria and fungi form many kinds of extracellular and intracellular associations. The
gene expression of bacterial as well as fungal pathogens can change in the presence of the other.
Bacteria-fungi interactions (BFI) are known in cheese, where the hyphae of Mucor fungi form
“superhighways”, through which the bacterial pathogens, such as Listeria, can spread [221]. There
are many bacterial-fungal co-infections of burn wounds and keratitis [222–229]. The lungs of
immuno-compromised individuals are often the sites of bacterial-fungal “superinfections”, notably
involving Pseudomonas aeruginosa and fungi, such as Candida albicans and Aspergillus fumigatus, which
may worsen lung function [227,230]. Clinical studies have been focused on the yeast Candida albicans
occurring in the buccal, dermal, and intestinal microbiomes, and a causative agent for a number of
infections [231]. In the presence of Candida albicans, Staphylococcus aureus shows enhanced biofilm
formation and resistance to vancomycin in serum [232–234]. Escherichia coli and Staphylococcus
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aureus are synergistic Candida albicans co-pathogens and cause increased mortality in animal models
of polymicrobial peritonitis [235–237]. Bacterial small molecules affect the critical yeast-hyphal
morphological transition of fungi during pathogenesis. This transition in Candida albicans is inhibited
by SCFA from lactic acid bacteria [238] and mutanobactin A from Streptococcus mutans [239]. Hyphal
growth is induced by cell wall peptidoglycan, while Candida albicans farnesol production modifies
bacterial virulence by interfering with quorum sensing [240,241]. Cryptococcus neoformans utilizes
homogentisic acid produced by Klebsiella aerogenes, as a precursor for melanin pigments, which protect
against ultraviolet radiation and cause increased virulence [242,243].
The presence of antibiotics exerts a selective pressure, which favors the survival of antibiotic
resistant fungi and bacteria. Physical contact and environmental cues, such as nutritional conditions,
can modulate co-adherence between Candida albicans and oral bacteria [244]. Staphylococcus aureus
associates with the hyphae of Candida species, which provides a mechanism for the bacterial invasion
of otherwise inaccessible tissues, such as epithelial layers [245]. Candida albicans strongly enhanced
the biofilm formation on polystyrene by Staphylococcus aureus, with the latter adhering to the fungal
hyphae in a poly-microbial biofilm rather than the plastic substrate [233]. Similar effects may be
important for the colonization of medical devices by a range of microbes [246]. Mixed bacterial-fungal
biofilms are of considerable medical interest due to their prevalence in certain infections [247] and
on the surface of medical devices, such as catheters, prostheses, and mechanical ventilators [248,249].
However, clinical therapies have been developed to target either fungal or bacterial infections, failing
to consider co-infection, with the mixed communities showing virulence and resistance properties
significantly different from those of the single species [228,229]. An understanding of BFI in human
health is, therefore, an important emerging medical challenge. However, not all BFI are pathogenic to
animal hosts. The first probiotic BFI effect was demonstrated by the use of Saccharomyces boulardii to
combat antibiotic-associated diarrhea caused by the loss of indigenous microbes after antibiotic
therapy and subsequent colonization by bacterial pathogens like Clostridium difficile [250]. The
protective effect of Saccharomyes boulardii has been attributed to mechanisms, such as the degradation
of Clostridium difficile toxins by yeast proteases and the alteration of E. coli lipopolysaccharide by
a yeast phosphatase [251–253]. In the presence of Saccharomyces boulardii, reductions in bacterial
adherence, colonization of intestinal epithelial cells, and expression of virulence factors were reported
for Citrobacter rodentium colon infections [254].
The role of predators in the ecology of macroscopic animals is well-established. Predation probably
plays an equally important role in microbial communities, but has received much less attention.
Obligate predatory bacteria that consume Gram-negative bacteria for nutrients and reproduction,
namely the Bdellovibrio and like organisms (BALOs), which include the genera Bdellovibrio, Bacteriovorax,
Peredibacter, and Halobacteriovorax [255,256]. BALOs were first used in agriculture in the 1970s as a
form of biological control for Pseudomonas syringae bacterial blight disease in soybeans [257]. Studies
on Bdellovibrio and Halobacteriovorax species increased in recent years and predatory bacteria are
beginning to be recognized as keystone species in their ecosystems, termed “living antibiotics” [258].
Both Bdellovibrio and Halobacteriovorax species can attack a variety of Gram-negative bacteria, such
as Caulobacter crescentus [255], Escherichia coli, Klebsiella pneumoniae [259], and Salmonella species [259],
and are therefore important in controlling potential human pathogens in soil and aquatic reservoirs.
Control of Vibrio cholerae in white-leg shrimps using Bdellovibrio bacteriovorus was demonstrated
in China recently [260]. The use of predatory bacteria to check the proliferation of pathogens in
aquaculture and animal husbandry, where antibiotic resistance is already a major issue, could be
crucial in controlling future outbreaks of food-borne diseases.
6.3. Wider Ecology and One Health
It is known that many pathogens have distinct life-cycles or life-cycle stages in different species of
hosts, some of which are merely reservoirs, while others suffer from disease symptoms. Salmonella
enterica, a human pathogen, benefits from interactions with plant pathogens [261]. It enters soft
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rot lesions in tomatoes and thrives in the company of Pectobacterium carotovorum, which secretes
enzymes to degrade plant cell-walls that it lacks. Other bacteria also protect plant surfaces, such
as edible leaves, against colonization by human pathogens such as Eshcerichia coli O157:H7 [262].
Some human pathogens have reservoirs in non-human animals and some have many hosts; for
example, Salmonella enterica serovar Typhimurium can infect around 40 metazoan species including
humans [263]. Therefore, the divide between human and veterinary medicine could be affecting efforts
to curb infectious diseases.
In the One Health view, human beings, farm animals, crops, and wildlife form an inter-connected
system. Managing disease outbreaks or the flow and disposal of antibiotics into ecological reservoirs,
such as soil or water, should not be isolated exercises aimed solely at human beings. Widespread
antibiotic resistance occurs among farm animals and in food products derived from them [264]. Pets,
feral animals, and wildlife also show the same trend [265]. In this context, an integrated approach to
monitor and restrict the use and dispersal of antibiotics via animal husbandry, medical waste, and
wastewater would certainly be beneficial in the long term. It has been suggested that the bush-meat
trade in infected bats reaching new population centers at the edge of formerly undisturbed forests
could have played a role in the most recent Ebola outbreak in West Africa. Thus, the opening up of
forests due to human population pressures and climate change may bring diseases once confined
to small populations of forest-dwellers into more thickly populated urban areas in the economically
less-developed regions of the world. This calls for the inclusion of animal and environmental health
in public health programs designed for poorer countries. Richer temperate zone countries in the
could also be affected by an increased incidence of infectious diseases spreading farther due to global
warming enhancing the survival rates of insects and other arthropod vectors at higher latitudes. Thus,
climate change would need to be taken into account in public health plans for these countries.
7. Conclusions
There have been a number of promising developments in the field of antimicrobials recently, as
outlined in this review. It takes 10–15 years for a new drug molecule to reach the market from its initial
discovery. Most of the molecules discussed in this article are still in the early stages of discovery; a few
have made it to clinical studies and they are listed in Table 4. Those in phase 3 clinical studies could
be expected to be on the market in the next few years. Nevertheless, many challenges remain and
technical developments alone will not be enough; major policy decisions and practical measures are
needed to fight infectious diseases. Even so, developments in such areas remain mixed. For example,
several large food corporations promised action on checking misuse of antibiotics in animal husbandry,
but troubling questions remain on the implementation, due to a lack of binding rules. Also, antibiotic
production facilities in many countries are not equipped to deal with pharmaceutical waste, and
as a result, widespread antibiotic resistance has been reported among bacteria in wastewater and
soil adjacent to effluent treatment plants [266,267]. The withholding of negative data from clinical
trials and the suppression of the structural details of new drugs via commercial patents also hinder
the multinational, multi-institutional, and multidisciplinary approaches needed to tackle epidemic
situations, like the 2015 Ebola outbreak. However, the development of the Zika vaccine demonstrated
more concerted action in the Americas, which is encouraging.
Up to 80 percent of antibiotics are prescribed by healthcare providers or purchased directly by
consumers or caregivers, without prescription in some countries [268]. Non-prescription antibiotics
were more likely to be used by patients in public health facilities, who were often less educated and
had lower annual incomes [269]. Greater efforts are thus needed in raising awareness about antibiotic
misuse among sections of the public with lower education and socio-economic status. Careful drug
management can reduce the incidence of drug-resistant infections and prolong the effectiveness of
antibiotic arsenals, according to a new study of ciprofloxacin use [269]. Under a stewardship program,
whereby a multidrug panel was tested with the mandate that ciprofloxacin susceptibility be reported
if, and only if, there was no other susceptibility. A strong reduction in ciprofloxacin use was observed,
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which correlated with increasing susceptibility in clinical Eshcerichia coli isolates towards this antibiotic.
Some countries already have stewardship programs in place, and a wider adoption of such programs
at the national and regional level could be beneficial globally in limiting the rise of resistance towards
various antibiotics. In the last few years, governmental agencies in the EU and the US have been more
proactive in framing guidelines for antibiotic use, which is encouraging. More coordination between
different players in the public health scenario and concerted efforts are needed to effectively tackle the
growing threat of antibiotic resistant infections.
Table 4. Some antibiotics recently evaluated in clinical studies.
Drug Molecule with Reference Clinical Phase Medical Condition
POL70780/Murepavadin [270] Phase 3 Pneumonia
Surotomycin [271] Phase 3 Diarrhea
Cethromycin (semi-synthetic) [272] Phase 3 Pneumonia
Solithromycin (semi-synthetic) [273,274] Phase 2 Uncomplicated urogenitalgonorrhea, Pneumonia
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